Literature DB >> 17359317

Empirical therapy for diabetic foot infections: are there clinical clues to guide antibiotic selection?

B A Lipsky.   

Abstract

Initial antibiotic therapy for diabetic foot infections is usually empirical. Several principles may help to avoid selecting either an unnecessarily broad or inappropriately narrow regimen. First, clinically severe infections require broad-spectrum therapy, while less severe infections may not. Second, aerobic Gram-positive cocci, particularly Staphylococcus aureus (including methicillin-resistant S. aureus (MRSA) for patients at high-risk) should always be covered. Third, therapy should also be targeted at aerobic Gram-negative pathogens if the infection is chronic or has failed to respond to previous antibiotic therapy. Fourth, anti-anaerobe agents should be considered for necrotic or gangrenous infections on an ischaemic limb. Parenteral therapy is needed for severe infections, but oral therapy is adequate for most mild or moderate infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17359317     DOI: 10.1111/j.1469-0691.2007.01697.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  17 in total

Review 1.  Methicillin-resistant Staphylococcus aureus in diabetic foot infections.

Authors:  Ioanna Eleftheriadou; Nicholas Tentolouris; Vasiliki Argiana; Edward Jude; Andrew J Boulton
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

2.  Changing microbiological profile of pathogenic bacteria in diabetic foot infections: time for a rethink on which empirical therapy to choose?

Authors:  P Ramakant; A K Verma; R Misra; K N Prasad; G Chand; A Mishra; G Agarwal; A Agarwal; S K Mishra
Journal:  Diabetologia       Date:  2010-09-11       Impact factor: 10.122

3.  Pyrosequencing reveals the complex polymicrobial nature of invasive pyogenic infections: microbial constituents of empyema, liver abscess, and intracerebral abscess.

Authors:  C D Sibley; D L Church; M G Surette; S E Dowd; M D Parkins
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-04-28       Impact factor: 3.267

4.  Variation in antibiotic treatment for diabetic patients with serious foot infections: a retrospective observational study.

Authors:  Benjamin G Fincke; Donald R Miller; Cindy L Christiansen; Robin S Turpin
Journal:  BMC Health Serv Res       Date:  2010-07-06       Impact factor: 2.655

5.  Spectrum and prevalence of fungi infecting deep tissues of lower-limb wounds in patients with type 2 diabetes.

Authors:  Gopi Chellan; Shashikala Shivaprakash; Sundaram Karimassery Ramaiyar; Ajit Kumar Varma; Narendra Varma; Mangalanandan Thekkeparambil Sukumaran; Jayakumar Rohinivilasam Vasukutty; Arun Bal; Harish Kumar
Journal:  J Clin Microbiol       Date:  2010-04-21       Impact factor: 5.948

Review 6.  The treatment of diabetic foot infections: focus on ertapenem.

Authors:  Michael Edmonds
Journal:  Vasc Health Risk Manag       Date:  2009-11-16

7.  Management of diabetic foot infections in an era of increasing microbial resistance.

Authors:  Sandra Bliss Nelson
Journal:  Curr Infect Dis Rep       Date:  2009-09       Impact factor: 3.725

8.  Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections.

Authors:  J Majcher-Peszynska; G Haase; M Sass; R Mundkowski; A Pietsch; S Klammt; W Schareck; B Drewelow
Journal:  Eur J Clin Pharmacol       Date:  2008-07-25       Impact factor: 2.953

9.  Concordance in diabetic foot ulcer infection.

Authors:  E Andrea Nelson; Michael Ross Backhouse; Moninder S Bhogal; Alexandra Wright-Hughes; Benjamin A Lipsky; Jane Nixon; Sarah Brown; Janine Gray
Journal:  BMJ Open       Date:  2013-01-04       Impact factor: 2.692

10.  Diabetic foot infections with osteomyelitis: efficacy of combined surgical and medical treatment.

Authors:  Abubakr H Widatalla; Seif Eldin I Mahadi; Mohamed A Shawer; Shadad M Mahmoud; A E Abdelmageed; Mohamed Elmakki Ahmed
Journal:  Diabet Foot Ankle       Date:  2012-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.